TGTX vs ZBH · P/E 18, rev $240.3M vs P/E 23, rev $8.23B
TG Therapeutics Inc (TGTX) versus Zimmer Biomet Holdings Inc (ZBH) — a side-by-side from cached financials, not a winner call.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Latest reported ZBH revenue for 2025-12-31 was $8.23B. Net income was $705.1M. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
TGTX currently screens at market cap $7.88B and trailing P/E 18.0. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
Not investment advice. Open the TGTX and ZBH stock pages for the full models.
Not investment advice.